Ohio State University Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ohio State University Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count).
Ohio State University Comprehensive Cancer Center: 341 sponsored US clinical trials, 77 recruiting.
Ohio State University Comprehensive Cancer Center sponsors 341 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 206 completed. 5 of these trials are in Phase 3-4 (later-stage) and 116 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anatomic Stage II Breast Cancer AJCC v8, with 10 trials.
Top-decile sponsor footprint
Ohio State University Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
206 of 217 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
341 total, page 6 of 7
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
NCT01653106
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
NCT01521039
Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans
NCT01692340
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
NCT01491958
Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery
NCT01646697
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT01460940
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
NCT01478477
Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery
NCT01660152
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
NCT01929720
Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer
NCT01644136
Community Awareness, Resources and Education (CARE II) Project: Project 1
NCT02797600
Cognitive Therapy in Reducing Depression in Patients With Cancer
NCT01748734
Community Awareness, Resources and Education (CARE II): Project 3
NCT01299714
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
NCT01640340
Fast Food, Fatigue, and Inflammation
NCT04247763
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
NCT02072356
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
NCT01212380
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
NCT01696760
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
NCT01764789
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
NCT01206777
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
NCT01764802
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
NCT02150525
Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention
NCT01282580
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
NCT01129206
Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease
NCT01656746
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
NCT01064921
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
NCT01682941
CBPR Strategies to Increase Colorectal Cancer Screening in Ohio Appalachia
NCT01904656
Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy
NCT00909896
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
NCT00834678
Testing Interventions to Motivate and Educate
NCT01568151
Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
NCT00841555
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease
NCT00754910
Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care
NCT01816841
Wound Dressings For Split-Thickness Skin Graft Donor Sites in Patients Undergoing Surgery
NCT01680367
Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors
NCT00816335
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00754923
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00729118
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
NCT00738361
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
NCT00675259
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT00624936
Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy
NCT01009736
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
NCT00569309
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
NCT00566540
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
NCT00561418
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT01469429
Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer
NCT01801059
Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors
NCT00486525
Communication & Peer Support Effects on Physical Activity in Overweight Postmenopausal Women
NCT01940016
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
NCT00983359
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 59 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Ohio State University Comprehensive Cancer Center pipeline
77 recruiting of 341 indexed (23% open); 206 completed (60%).
Phase mix: 5 late (III/IV) vs 116 early (I/II) (early-phase heavy).
Top condition: Anatomic Stage II Breast Cancer AJCC v8 (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ohio State University Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 341 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 341 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
Sponsors near 23% open enrollment (± trial volume)
- University of Delaware · 23% recruiting · 106 trials
- University of Virginia · 22% recruiting · 449 trials
- University of Kansas Medical Center · 23% recruiting · 408 trials
- University of Oklahoma · 22% recruiting · 358 trials
Related
What to do with this Ohio State University Comprehensive Cancer Center page
341 registered trials is a research-attention snapshot, not an endorsement of Ohio State University Comprehensive Cancer Center or any single study.
- 77 of Ohio State University Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Anatomic Stage II Breast Cancer AJCC v8 is the condition Ohio State University Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anatomic Stage II Breast Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ohio State University Comprehensive Cancer Center pipeline card: 341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.